Pasture Holdings' Earnings Rebound in FY 2024
Pasture Holdings' Earnings Rebound in FY 2024
The mask and medical supplies business also grew 300% to $201,434 (US$154,000) from $58,860 (US$45,000) in FY 2023.The company has rebounded from a net loss of US$1.3m to a net profit of US$0.6m.
公司從130萬美元的淨虧損中反彈，實現了60萬美元的淨利潤。
Pasture Holdings rebounded from a net loss of $1.7m (US$1.3m) to a net profit of $0.73m (US$0.6m) in FY 2024.
Pasture Holdings從170萬美元（1.3百萬美元）的淨虧損反彈至73萬美元（0.6百萬美元）的淨利潤，截至2024財年。
Revenue for the period surged 44.9% year-on-year (YoY) to $18.3m (US$14.0m), driven by a 43..7% YoY growth in its pharmaceutical business which recorded a revenue of $18.2m (US$13.9m) with new customer acquisitions and more orders from existing customers.
該期營業收入同比激增44.9%，達到1830萬美元（14.0百萬美元），主要由醫藥商業實現了43.7%的同比增長，錄得1820萬美元（13.9百萬美元）的營業收入，受益於新客戶的獲取以及現有客戶訂單的增加。
The mask and medical supplies business also grew 300% to $201,434 (US$154,000) from $58,860 (US$45,000) in FY 2023.
口罩和醫療產品業務的營業額也增長了300%，從2023財年的58,860美元（45,000美元）增至201,434美元（154,000美元）。
Meanwhile, gross profit more than doubled to $4.6m (US$3.5m) due to higher revenue and related operational efficiencies achieved.
與此同時，毛利潤由460萬美元（3.5百萬美元）翻了一番，得益於營業收入的增加以及相關運營效率的提高。
Pasture Holdings maintains a positive outlook amidst favourable structural trends such as the ageing global population, an enlarged cold chain warehouse capacity, and potential growth in new non-core business
Pasture Holdings對未來保持樂觀態度，受益於有利的結構性趨勢，例如全球人口老齡化、冷鏈倉儲能力的擴大，以及新的非核心業務的潛在增長。